Stoke Therapeutics, Inc. (NASDAQ:STOK) to Post Q2 2024 Earnings of ($0.43) Per Share, Leerink Partnrs Forecasts
The Cerbat Gem - 2024-04-14T01:16:41.000Z

Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Analysts at Leerink Partnrs issued their Q2 2024 earnings per share (EPS) estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst R. Li forecasts that the company will post earnings per share of ($0.43) for the quarter. The […] Read this story